The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Bavarian Nordic Secures DKK 200 Million Contract for Smallpox/Mpox Vaccine Supply to European Country.
Jul 09, 2025•11 months ago
Contract Type
contract
BiotechnologyHealth Care
Description
Bavarian Nordic A/S has announced a contract valued at over DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed European country. This order is part of efforts to strengthen national preparedness against biological threats and epidemics.
Company Information
Company
Bavarian Nordic
About
Bavarian Nordic is a biotechnology company focused on developing and producing innovative vaccines. The company's portfolio includes treatments for infectious diseases and cancer. It is publicly traded and based in Denmark.
Predictive Intelligence
Strategic
ML-powered predictions for Bavarian Nordic's next move
